IRB Study Number 19-1618
Status Recruiting
Location Cleveland Clinic Main Campus
Institute Taussig Cancer Institute
Description
Primary Objective
To evaluate the prevalence of clonal hematopoiesis on the peripheral blood, bone marrow, and/or surgical specimen in the upfront clinical setting and survivorship clinic using the in-house next generation sequencing panel.
Secondary Objective(s)
- To evaluate clinical outcomes associated with the presence of clonal disorders
- To assess the potential clinical implications of identifying germline variants in this population.
Inclusion Criteria
Subjects must have a solid tumor or hematologic malignancy with a confirmed histopathology Patients actively in survivorship care at the Cleveland Clinic are also eligible.
Subjects may have a non-malignant disorder of special interest, including:
a. Non-malignant hematological disorder
b. Cardiovascular disease
c. Rheumatological illness
d. Neuropsychiatric illness
e. endocrine disorders
Patients with lung disease. Patients with lung disease have environmental, genetic, inflammatory, and medication exposures related to their diagnosis that create a unique combination of risk factors for Clonal hematopoiesis.
Age ≥18 years
Pregnant women may choose to consent if they would like to participate in the study as there is no added risk to the pregnancy.
Subjects must be able to give informed consent
Exclusion Criteria
- Patients on active systemic cytotoxic chemotherapy, immunotherapy or targeted therapy other than endocrine therapy
